RATIONALE: S-citalopram (escitalopram) is the very active moiety of citalopram. It has been shown in many studies to be an effective and safe antidepressant for treating major depressive disorder (MDD). OBJECTIVE: The aim of our study was to compare the efficacy and safety of escitalopram vs citalopram in Chinese MDD patients. METHODS: In the double-blind study, 240 MDD patients were randomly assigned to treatment for 6 weeks either with escitalopram (10-20 mg/d) or citalopram (20-40 mg/d). The primary efficacy measurement was the change of 17-item Hamilton Depression Rating Scale (HAMD-17) total score from baseline to the end of study. The secondary efficacy measurements were response and remission rates. The adverse events (AEs) were recorded by the investigator. RESULTS:Two hundred and three (85%) patients completed the trial. The average dose was 13.9 mg/d in the escitalopram group and 27.6 mg/d in the citalopram group. No significant differences were found between the two groups in the change in HAMD-17 total score, response, and remission rate. These results were similar in severe MDD patients. No significant differences were found between the two groups in AEs. No serious AEs were observed in this study. CONCLUSIONS: The study suggests that escitalopram 10-20 mg/d are as effective and safe as citalopram 20-40 mg/d in the short-term treatment for Chinese MDD patients.
RCT Entities:
RATIONALE: S-citalopram (escitalopram) is the very active moiety of citalopram. It has been shown in many studies to be an effective and safe antidepressant for treating major depressive disorder (MDD). OBJECTIVE: The aim of our study was to compare the efficacy and safety of escitalopram vs citalopram in Chinese MDDpatients. METHODS: In the double-blind study, 240 MDDpatients were randomly assigned to treatment for 6 weeks either with escitalopram (10-20 mg/d) or citalopram (20-40 mg/d). The primary efficacy measurement was the change of 17-item Hamilton Depression Rating Scale (HAMD-17) total score from baseline to the end of study. The secondary efficacy measurements were response and remission rates. The adverse events (AEs) were recorded by the investigator. RESULTS: Two hundred and three (85%) patients completed the trial. The average dose was 13.9 mg/d in the escitalopram group and 27.6 mg/d in the citalopram group. No significant differences were found between the two groups in the change in HAMD-17 total score, response, and remission rate. These results were similar in severe MDDpatients. No significant differences were found between the two groups in AEs. No serious AEs were observed in this study. CONCLUSIONS: The study suggests that escitalopram 10-20 mg/d are as effective and safe as citalopram 20-40 mg/d in the short-term treatment for Chinese MDDpatients.
Authors: Valery Y Yevtushenko; Alexander I Belous; Yevgenia G Yevtushenko; Sergei E Gusinin; Oleg J Buzik; Tatiana V Agibalova Journal: Clin Ther Date: 2007-11 Impact factor: 3.393
Authors: Vaya Lalit; Prakash M Appaya; Rajendra P Hegde; Anukant K Mital; Sunil Mittal; Rajesh Nagpal; Vaiapuri Palaniappun; C Ramsubramaniam; Gundugurti P Rao; Krishna Roy; Jitendra K Trivedi; Ganpat K Vankar; Rajesh S Karan; Sweety Shah; Ronak B Patel Journal: Indian J Psychiatry Date: 2004-10 Impact factor: 1.759
Authors: Barbara Nussbaumer; Laura C Morgan; Ursula Reichenpfader; Amy Greenblatt; Richard A Hansen; Megan Van Noord; Linda Lux; Bradley N Gaynes; Gerald Gartlehner Journal: CNS Drugs Date: 2014-08 Impact factor: 5.749
Authors: Bret R Rutherford; Timothy M Cooper; Amanda Persaud; Patrick J Brown; Joel R Sneed; Steven P Roose Journal: J Clin Psychiatry Date: 2013-07 Impact factor: 4.384